CS for SB 710

By the Committee on Health Policy; and Senator Book

| | 588-01792-18 2018710c1 |
|----|--|
| 1 | A bill to be entitled |
| 2 | An act relating to the Prescription Drug Donation |
| 3 | Program; amending s. 499.029, F.S.; renaming the |
| 4 | Cancer Drug Donation Program as the Prescription Drug |
| 5 | Donation Program; authorizing the donation of |
| 6 | prescription drugs, including cancer drugs, and |
| 7 | supplies to eligible patients; revising definitions; |
| 8 | authorizing nursing home facilities to participate in |
| 9 | the program; providing an effective date. |
| 10 | |
| 11 | Be It Enacted by the Legislature of the State of Florida: |
| 12 | |
| 13 | Section 1. Section 499.029, Florida Statutes, is amended to |
| 14 | read: |
| 15 | 499.029 Prescription Cancer Drug Donation Program |
| 16 | (1) This section may be cited as the " <u>Prescription</u> Cancer |
| 17 | Drug Donation Program Act." |
| 18 | (2) There is created a <u>Prescription</u> Cancer Drug Donation |
| 19 | Program within the department for the purpose of authorizing and |
| 20 | facilitating the donation of prescription cancer drugs and |
| 21 | supplies to eligible patients. |
| 22 | (3) As used in this section: |
| 23 | (a) "Cancer drug" means a prescription drug that has been |
| 24 | approved under s. 505 of the Federal Food, Drug, and Cosmetic |
| 25 | Act and is used to treat cancer or its side effects or is used |
| 26 | to treat the side effects of a prescription drug used to treat |
| 27 | cancer or its side effects. <u>The term</u> "Cancer drug" does not |
| 28 | include a substance listed in Schedule II, Schedule III, |
| 29 | Schedule IV, or Schedule V of s. 893.03. |
| • | Page 1 of 7 |

588-01792-18 2018710c1 30 (b) "Closed drug delivery system" means a system in which 31 the actual control of the unit-dose medication package is 32 maintained by the facility rather than by the individual 33 patient. 34 (c) "Donor" means a patient or patient representative who 35 donates prescription cancer drugs or supplies needed to 36 administer prescription cancer drugs that have been maintained 37 within a closed drug delivery system; health care facilities, nursing home facilities homes, hospices, or hospitals with 38 39 closed drug delivery systems; or pharmacies, drug manufacturers, 40 medical device manufacturers or suppliers, or wholesalers of drugs or supplies, in accordance with this section. The term 41 42 "Donor" includes a physician licensed under chapter 458 or chapter 459 who receives prescription cancer drugs or supplies 43 44 directly from a drug manufacturer, wholesale distributor, or 45 pharmacy. 46 (d) "Eligible patient" means a person who the department 47 determines is eligible to receive prescription cancer drugs from 48 the program. 49 (e) "Participant facility" means a hospital that operates a 50 class II institutional hospital pharmacy or a nursing home 51 facility licensed under part II of chapter 400 with a closed 52 drug delivery system that has elected to participate in the 53 program and that accepts donated prescription cancer drugs and 54 supplies under the rules adopted by the department for the 55 program.

(f) "Prescribing practitioner" means a physician licensed
under chapter 458 or chapter 459 or any other medical
professional with authority under state law to prescribe

Page 2 of 7

588-01792-18 2018710c1 59 prescription drugs cancer medication. 60 (g) "Prescription drug" has the same meaning as provided in s. 499.003, and includes cancer drugs. The term does not include 61 62 a substance listed in Schedule II, Schedule III, Schedule IV, or 63 Schedule V of s. 893.03. 64 (h) (g) "Program" means the Prescription Cancer Drug 65 Donation Program created by this section. (i) (h) "Supplies" means any supplies used in the 66 67 administration of a prescription cancer drug. 68 (4) Any donor may donate prescription cancer drugs or 69 supplies to a participant facility that elects to participate in 70 the program and meets criteria established by the department for 71 such participation. Prescription Cancer drugs or supplies may 72 not be donated to a specific cancer patient, and donated drugs 73 or supplies may not be resold by the program. Prescription 74 Cancer drugs billed to and paid for by Medicaid in long-term 75 care facilities that are eligible for return to stock under 76 federal Medicaid regulations shall be credited to Medicaid and 77 are not eligible for donation under the program. A participant 78 facility may provide dispensing and consulting services to 79 individuals who are not patients of the hospital or nursing home 80 facility. 81 (5) The prescription cancer drugs or supplies donated to 82 the program may be prescribed only by a prescribing practitioner 83 for use by an eligible patient and may be dispensed only by a pharmacist. 84 85 (6) (a) A prescription cancer drug may only be accepted or 86 dispensed under the program if the drug is in its original, 87 unopened, sealed container, or in a tamper-evident unit-dose

Page 3 of 7

588-01792-18 2018710c1 88 packaging, except that a prescription cancer drug packaged in 89 single-unit doses may be accepted and dispensed if the outside 90 packaging is opened but the single-unit-dose packaging is 91 unopened with tamper-resistant packaging intact. 92 (b) A prescription cancer drug may not be accepted or dispensed under the program if the drug bears an expiration date 93 94 that is less than 6 months after the date the drug was donated 95 or if the drug appears to have been tampered with or mislabeled as determined in paragraph (c). 96 97 (c) Prior to being dispensed to an eligible patient, the 98 prescription cancer drug or supplies donated under the program shall be inspected by a pharmacist to determine that the drug 99 100 and supplies do not appear to have been tampered with or 101 mislabeled. 102 (d) A dispenser of donated prescription cancer drugs or 103 supplies may not submit a claim or otherwise seek reimbursement 104 from any public or private third-party payor for donated 105 prescription cancer drugs or supplies dispensed to any patient 106 under the program, and a public or private third-party payor is 107 not required to provide reimbursement to a dispenser for donated 108 prescription cancer drugs or supplies dispensed to any patient 109 under the program.

(7) (a) A donation of <u>prescription</u> cancer drugs or supplies shall be made only at a participant facility. A participant facility may decline to accept a donation. A participant facility that accepts donated <u>prescription</u> cancer drugs or supplies under the program shall comply with all applicable provisions of state and federal law relating to the storage and dispensing of the donated <u>prescription</u> cancer drugs or supplies.

Page 4 of 7

588-01792-18 2018710c1 117 (b) A participant facility that voluntarily takes part in 118 the program may charge a handling fee sufficient to cover the 119 cost of preparation and dispensing of prescription cancer drugs 120 or supplies under the program. The fee shall be established in 121 rules adopted by the department. (8) The department, upon the recommendation of the Board of 122 123 Pharmacy, shall adopt rules to carry out the provisions of this 124 section. Initial rules under this section shall be adopted no 125 later than 90 days after the effective date of this act. The rules shall include, but not be limited to: 126 127 (a) Eligibility criteria, including a method to determine 128 priority of eligible patients under the program. 129 (b) Standards and procedures for participant facilities 130 that accept, store, distribute, or dispense donated prescription 131 cancer drugs or supplies. 132 (c) Necessary forms for administration of the program, 133 including, but not limited to, forms for use by entities that 134 donate, accept, distribute, or dispense prescription cancer 135 drugs or supplies under the program. 136 (d) The maximum handling fee that may be charged by a 137 participant facility that accepts and distributes or dispenses 138 donated prescription cancer drugs or supplies. 139 (e) Categories of prescription cancer drugs and supplies 140 that the program will accept for dispensing; however, the 141 department may exclude any drug based on its therapeutic effectiveness or high potential for abuse or diversion. 142 143 (f) Maintenance and distribution of the participant 144 facility registry established in subsection (10). 145 (9) A person who is eligible to receive prescription cancer

Page 5 of 7

CODING: Words stricken are deletions; words underlined are additions.

CS for SB 710

CS for SB 710

588-01792-18 2018710c1 146 drugs or supplies under the state Medicaid program or under any 147 other prescription drug program funded in whole or in part by 148 the state, by any other prescription drug program funded in whole or in part by the Federal Government, or by any other 149 150 prescription drug program offered by a third-party insurer, unless benefits have been exhausted, or a certain prescription 151 152 cancer drug or supply is not covered by the prescription drug 153 program, is ineligible to participate in the program created under this section. 154

(10) The department shall establish and maintain a 155 participant facility registry for the program. The participant 156 157 facility registry shall include the participant facility's name, 158 address, and telephone number. The department shall make the 159 participant facility registry available on the department's 160 website to any donor wishing to donate prescription cancer drugs 161 or supplies to the program. The department's website shall also 162 contain links to prescription cancer drug manufacturers that 163 offer drug assistance programs or free medication.

164 (11) Any donor of prescription cancer drugs or supplies, or 165 any participant in the program, who exercises reasonable care in donating, accepting, distributing, or dispensing prescription 166 167 cancer drugs or supplies under the program and the rules adopted 168 under this section shall be immune from civil or criminal 169 liability and from professional disciplinary action of any kind for any injury, death, or loss to person or property relating to 170 171 such activities.

(12) A pharmaceutical manufacturer is not liable for any
 claim or injury arising from the transfer of any prescription
 cancer drug under this section, including, but not limited to,

Page 6 of 7

CS for SB 710

| i | 588-01792-18 2018710c1 |
|-----|---|
| 175 | liability for failure to transfer or communicate product or |
| 176 | consumer information regarding the transferred drug, as well as |
| 177 | the expiration date of the transferred drug. |
| 178 | (13) If any conflict exists between the provisions in this |
| 179 | section and the provisions in this chapter or chapter 465, the |
| 180 | provisions in this section shall control the operation of the |
| 181 | Prescription Cancer Drug Donation Program. |
| 182 | Section 2. This act shall take effect July 1, 2018. |
| | |

Page 7 of 7